Hepatocellular Carcinoma Occurrence/Recurrence after Direct-Acting Antivirals for Hepatitis C in Egyptian Cohort: Single-Center Experience
| Autor: | Sameh A Lashen, Mohammed Mohammed Shamseya, Marwa A. Madkour |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Cirrhosis Carcinoma Hepatocellular Kaplan-Meier Estimate Single Center DIRECT ACTING ANTIVIRALS Gastroenterology Antiviral Agents 03 medical and health sciences 0302 clinical medicine Fibrosis Risk Factors Internal medicine medicine Humans neoplasms Retrospective Studies business.industry Incidence (epidemiology) Liver Neoplasms General Medicine Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease digestive system diseases 030220 oncology & carcinogenesis Hepatocellular carcinoma Cohort 030211 gastroenterology & hepatology Egypt Female Neoplasm Recurrence Local business |
| Zdroj: | Digestive diseases (Basel, Switzerland). 37(6) |
| ISSN: | 1421-9875 |
| Popis: | Background: Conflicting data have been published about the risk of hepatocellular carcinoma (HCC) following direct-acting antivirals (DAAs). We investigated the incidence of HCC occurrence/recurrence after DAAs therapy. Patients and Methods: Retrospectively, we analyzed data of 392 patients with F3–4 fibrosis and cirrhosis treated by DAAs during the period from August 2015 to May 2018. In HCC-experienced patients, HCC treatment modality, and the duration between HCC management and DAAs initiation were recorded. In all patients, pretreatment clinicolaboratory evaluation, and imaging before, during and after DAAs were done. Results: De novo HCC occurred in 7.6% of naïve patients, while recurrence appeared in 28% of patients with previous HCC. Pretreatment alpha-fetoprotein was an independent predictor of HCC occurrence, while the time between HCC ablation and the beginning of DAAs was the only predictor of HCC recurrence (p < 0.001). Half of the patients who started DAAs before 6 months had HCC recurrence, while patients who started DAAs at ≥6 months had no recurrence (p< 0.0001). Conclusions: Although HCC occurrence after DAAs was not high, recurrence was apparently high. Pretreatment alpha-fetoprotein is a predictor for de novo HCC. The time between HCC ablation and DAAs was the strongest predictor of recurrence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|